Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares changing hands.
Oncolytics Biotech Price Performance
The company has a debt-to-equity ratio of 14.58, a current ratio of 2.88 and a quick ratio of 8.86. The stock has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The stock has a 50 day moving average price of C$14.90 and a 200-day moving average price of C$14.90.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Recommended Stories
- Five stocks we like better than Oncolytics Biotech
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
